It looks like the biggest pharma merger of the year so far is on, after Shire recommended shareholders accept a bid from Takeda worth around £46 billion. After a series of bids from the Japanese ...

Takeda’s CEO has said he is confident that its $62 billion acquisition of Shire will go ahead, despite a rebellion from a dissident group of shareholders. Christophe Weber spoke on the matter at ...

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited ... rapid deleveraging following its acquisition of Shire. “The divestment of non-core assets sold in NEMEA represents ...

A new appointee with more than two decades of comms experience will soon take the reins of Takeda’s worldwide brand strategy. The Big Pharma has selected Anne de Schweinitz to serve as head of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Please verify your email address. A post made on Tales of the Shire's X page suggests its fishing mini-game may not pay off in the long run, but that hopefully won't be the case. This failure was ...

Tales of the Shire is the coziest take on the Lord of the Rings universe yet, putting players in the shoes of a Hobbit in the midst of Hobbiton and tasking them with uniting the community ...

Please verify your email address. The Shire's isolation limits popular character appearances, but Radagast the Brown brings a unique charm to the game. Radagast's love for nature and simple ...

OSAKA, Japan & CAMBRIDGE, Mass., September 19, 2024--Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE ...